ABT — Abbott Laboratories Cashflow Statement
0.000.00%
Last trade - 00:00
- $186.15bn
- $193.77bn
- $40.11bn
- 85
- 26
- 75
- 66
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 3,687 | 4,495 | 7,071 | 6,933 | 5,723 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 766 | 971 | 695 | 900 | 770 |
Discontinued Operations | |||||
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -1,331 | -892 | -771 | -1,519 | -2,475 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Cash from Operating Activities | 6,136 | 7,901 | 10,533 | 9,581 | 7,261 |
Capital Expenditures | -1,638 | -2,177 | -1,885 | -1,777 | -2,202 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -177 | -38 | -123 | 37 | -931 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -1,815 | -2,215 | -2,008 | -1,740 | -3,133 |
Financing Cash Flow Items | 0 | -11 | 0 | — | — |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -4,289 | -2,779 | -5,494 | -7,636 | -7,091 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 16 | 2,978 | 2,961 | 83 | -2,986 |